1-3 of 3
Julia Braverman, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy

Tanya Siddiqi, MD, Ulrich Jaeger, MD, Olga Moshkovich, MPH, Jennifer Devlen, PhD, Matthew Miera, BSc, Agnes Williams, MSc, Jens Hasskarl, MD, Fei Fei Liu, BSc, MBA, Julia Braverman, PhD, Gilles Salles, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-137656
Published: 2020
Journal Articles

Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial

Michel Delforge, Nina Shah, MD, Paula Rodriguez-Otero, Parameswaran Hari, MD MRCP, Julia Braverman, PhD, Andrew Trigg, Payal Patel, Liping Huang, PhD, Kristen Hege, Sujith Dhanasiri
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-136677
Published: 2020
Journal Articles

Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial

Nina Shah, MD, Michel Delforge, Jesús F. San-Miguel, Kaitlyn B. Bertin, Muna J Tahir, Hannah B. Lewis, Julie Wang, PharmD, PhD, Julia Braverman, PhD, Timothy B. Campbell, MD PhD, Devender Dhanda, Nikhil C. Munshi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-136665
Published: 2020